



Loxapine

Catalog No: tcsc1105



Available Sizes

Size: 100mg

Size: 500mg



Specifications

CAS No:

1977-10-2

Formula:

 $\mathsf{C_{18}H_{18}CIN_3O}$

Pathway:

Neuronal Signaling; GPCR/G Protein

Target:

5-HT Receptor;5-HT Receptor

Purity / Grade:

>98%

Solubility:

DMSO : \geq 33.33 mg/mL (101.67 mM)

Observed Molecular Weight:

327.81

Product Description

Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.

IC50 value:

Target: D2DR/D4DR; 5-HT receptor





in vitro: In the presence of Loxapine, [3H]ketanserin binds to 5-HT2 receptor in Frontal cortex of brain in human and bovine with ki value of 6.2 nM and 6.6 nM, respectively. Loxapine has the rank order of potency for the various receptors appears to be as follows:5-HT2 \geq D4>>>D1>D2 in comparing competition experiments involving the human membranes [1]. Loxapine 0.2 μ M, 2 μ M and 20 μ M reduces IL-1beta secretion by LPS-activated mixed glia cultures after 1 and 3 days of exposure. Loxapine in concentrations of 0.2 μ M, 2 μ M and 20 μ M reduces IL-2 secretion in mixed glia cultures after 1 and 3 days of exposure, and additionally Loxapine decreases IL-1beta and IL-2 secretion in LPS-induced microglia cultures in concentrations of 2 μ M, 10 μ M and 20 μ M [2].

in vivo: Loxapine (5 mg/kg) induces a very significant reduction (more than 50%) of serotonin (S2) receptor density after 4 weeks or 10 weeks of daily injection in the rat. Loxapine (5 mg/kg) does not change dopamine receptor density but greatly reduces serotonin receptor density by 47% in the brain of rats [3].

$$N = CI$$

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!